A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

Inclusion Criteria: 1. ≥18 years old. 2. Subjects with recurrent or metastatic solid tumors that cannot accept radical locoregional therapy; 3. Systemic standard treatment failed or cannot tolerate serious toxicity or lack of standard treatment. 4. Have 1 or more focus can be accessed according to RECIST 1.1 5. Eastern Cooperative Oncology Group(ECOG):0-1 6. Expected survival period over 3 months 7. Have acceptable organ function and the results of laboratory examination meet the request below: Hepatic Insufficiency (ALT) and Aspartate aminotransferase（AST）≤3xULN(upper limit of normal);Total Bilirubin≤3xULN；Creatinine≤3xULN；White blood cell count ≥3.0x10\^9/L; Absolute Neutrophil Count≥1.0x10\^9/L 8. Agree to contraception 9. Subjects who understand and voluntarily sign the Informed Consent Form（ICF) Exclusion Criteria: 1. Central nervous system metastasis or meningeal metastasis with clinical symptoms； 2. With active infection during screening 3. Have serious or uncontrolled basic diseases; 4. Have continuous adverse event caused by previous anti-tumor therapy that might affect the evaluation of drug safety； 5. Accept anti-tumor therapy within 28 days before first injection; 6. Accept general anesthesia surgery or radiation therapy within 28 days before first injection; 7. Accept live vaccine or attenuated live vaccine within 28 days before first injection; 8. Allergy to known drug components; 9. Serous cavity effusion requiring clinical intervention； 10. Pregnancy or prepare to pregnant during the treatment; 11. Other situations that not suitable to participate into this trial.